Inhibitor Therapeutics, Inc. (INTI) - Annual Update

I am writing this guide to help you understand how Inhibitor Therapeutics, Inc. (INTI) performed this year. My goal is to explain their complex financial filings in plain English so you can decide if this company fits your investment goals.

1. What does this company do?

Inhibitor Therapeutics is a research firm that repurposes existing, FDA-approved drugs to treat new conditions. Their main focus is BCCNS (Gorlin Syndrome), a rare genetic condition where patients develop dozens or even hundreds of skin tumors over their lifetime.

Currently, these patients rely on repeated, painful surgeries to remove tumors. INTI aims to prove that their version of a drug called Itraconazole can manage these tumors systemically, potentially reducing the need for constant surgery. The company keeps costs low by outsourcing clinical development and manufacturing, focusing instead on regulatory strategy and patents.

2. Recent Progress: The "Catch-Up" Phase

After years of legal battles, the company is moving forward with the following developments:

• FDA Engagement: In early 2026, they requested a meeting with the FDA to discuss their path to approval for Itraconazole. They are using data from a 38-patient study, which showed a significant reduction in new tumors, to advocate for a faster approval process.
• New Formulation: They partnered with Avior to develop "Micro-ITRA," a version of the drug the body absorbs more easily. This formulation also provides patent protection through 2040, helping them defend against generic competitors.

3. The Financial Reality

The company is currently "pre-revenue," meaning they generated $0 in sales last year. They are funding their operations through cash reserves.

• Operating Costs: The company reported an annual operating loss of about $2.4 million, driven by research and administrative expenses. With less than $1 million in cash, the company notes that it may require additional funding within the next 12 months to continue operations.
• The Dilution Risk: Because they have no sales, they rely on selling more stock to raise capital. In the last 18 months, they increased the number of shares by about 15%. This practice, used to cover their $200,000 monthly burn rate, reduces the ownership percentage of existing shareholders.

4. Key Risks: A High-Stakes Bet

• Clinical Hurdles: The FDA may determine that the 38-patient study is insufficient, potentially requiring a new, multi-year trial costing $15–$20 million.
• Market Size and Access: The market for BCCNS is limited to 10,000 to 15,000 U.S. patients. If the drug is priced too high, insurance coverage may be restricted, which would limit potential sales.
• Competition: They face competition from established drugs like Erivedge and Odomzo. INTI must demonstrate that their drug is safer or more cost-effective to gain traction with doctors and patients.

5. Future Outlook

The company’s survival hinges on the FDA’s response to their 2026 meeting request. If the FDA allows a faster, more affordable approval path, the company could reach the market relatively soon. If the FDA requires a large-scale trial, the company will likely need to secure a partner or pursue a buyout, as they currently lack the capital to launch the drug independently.

Investor Takeaway: This is a high-risk, early-stage company. Before investing, consider whether you are comfortable with the significant dilution risk and the binary nature of their upcoming FDA interactions. Use this as a starting point for your own due diligence.